Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Among patients with hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer who had received one or more lines of endocrine-based therapy, treatment with trastuzumab deruxtecan resulted in longer progression-free survival than chemotherapy. No new safety signals were identified. (Funded by AstraZeneca and Daiichi Sankyo; DESTINY-Breast06 ClinicalTrials.gov number, NCT04494425.).
Authors
- Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
- Gargi Patel (ORCID: https://orcid.org/0000-0002-5268-4753)
- Jun Ke (ORCID: https://orcid.org/0009-0004-6918-2807)
- Jean‐Yves Pierga (ORCID: https://orcid.org/0000-0002-2863-9995)
- Kan Yonemori (ORCID: https://orcid.org/0000-0002-7624-7611)
- Joohyuk Sohn (ORCID: https://orcid.org/0000-0002-2303-2764)
- Aditya Bardia (ORCID: https://orcid.org/0000-0003-4885-1157)
- Joyce O’Shaughnessy (ORCID: https://orcid.org/0000-0002-2955-5523)
- Christelle Lévy (ORCID: https://orcid.org/0000-0003-0572-5222)
- Laura Biganzoli (ORCID: https://orcid.org/0000-0001-7989-8658)
- William Jacot (ORCID: https://orcid.org/0000-0001-7834-061X)
- Rebecca Dent (ORCID: https://orcid.org/0000-0001-6421-7602)
- Seock‐Ah Im (ORCID: https://orcid.org/0000-0002-5396-6533)
- Cristina Saura (ORCID: https://orcid.org/0000-0001-8296-5065)
- Natasha Begbie
- Qingyuan Zhang (ORCID: https://orcid.org/0000-0002-1763-9412)
- Xichun Hu (ORCID: https://orcid.org/0000-0002-2157-2695)
- Carlos H. Barrios (ORCID: https://orcid.org/0000-0001-6021-667X)
- Hans Wildiers
Institutions
- Harbin Medical University (CN)
- Université Paris Cité (FR)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-09-15
- DOI
- https://doi.org/10.1056/nejmoa2407086
- Citations
- 317
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 132.38
Funders
- AstraZeneca